Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group

PURPOSE: To evaluate the efficacy and tolerability of bortezomib in combination with doxorubicin in patients with advanced hepatocellular carcinoma, and to correlate pharmaco-dynamic markers of proteasome inhibition with response and survival. Experimental Design This phase II, open-label, multi-cen...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Ciombor, Kristen K., Feng, Yang, Benson, Al Bowen, Su, Yingjun, Horton, Linda, Short, Sarah P., Kauh, John Sae Wook, Staley, Charles, Mulcahy, Mary, Powell, Mark, Amiri, Katayoun I., Richmond, Ann, Berlin, Jordan
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4171216/
https://ncbi.nlm.nih.gov/pubmed/24890858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0111-8
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi